HK1214860A1 - 作為 型鈣通道阻滯劑的取代的吡唑 - Google Patents
作為 型鈣通道阻滯劑的取代的吡唑Info
- Publication number
- HK1214860A1 HK1214860A1 HK16102720.5A HK16102720A HK1214860A1 HK 1214860 A1 HK1214860 A1 HK 1214860A1 HK 16102720 A HK16102720 A HK 16102720A HK 1214860 A1 HK1214860 A1 HK 1214860A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- calcium channel
- channel blockers
- type calcium
- substituted pyrazoles
- pyrazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261683777P | 2012-08-16 | 2012-08-16 | |
PCT/US2013/055271 WO2014028803A1 (en) | 2012-08-16 | 2013-08-16 | Substituted pyrazoles as n-type calcium channel blockers |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1214860A1 true HK1214860A1 (zh) | 2016-08-05 |
Family
ID=49036655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16102720.5A HK1214860A1 (zh) | 2012-08-16 | 2016-03-11 | 作為 型鈣通道阻滯劑的取代的吡唑 |
Country Status (19)
Country | Link |
---|---|
US (1) | US8901314B2 (zh) |
EP (1) | EP2885293B1 (zh) |
JP (2) | JP2015524852A (zh) |
KR (1) | KR20150042834A (zh) |
CN (2) | CN104903316B (zh) |
AU (2) | AU2013302471B2 (zh) |
BR (1) | BR112015003395A2 (zh) |
CA (1) | CA2882123C (zh) |
CL (1) | CL2015000358A1 (zh) |
CR (1) | CR20150069A (zh) |
EA (1) | EA201590380A1 (zh) |
ES (1) | ES2600743T3 (zh) |
HK (1) | HK1214860A1 (zh) |
IL (1) | IL237191A0 (zh) |
MX (1) | MX2015002038A (zh) |
PE (1) | PE20151140A1 (zh) |
PH (1) | PH12015500315A1 (zh) |
SG (1) | SG11201501137VA (zh) |
WO (1) | WO2014028803A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9974775B2 (en) | 2013-08-16 | 2018-05-22 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150042269A (ko) | 2012-08-16 | 2015-04-20 | 얀센 파마슈티카 엔.브이. | N형 칼슘 채널 차단제로서의 치환된 피라졸 |
ES2894919T3 (es) | 2015-06-12 | 2022-02-16 | Vettore Llc | Inhibidores de MCT4 para el tratamiento de enfermedades |
KR101743960B1 (ko) | 2015-07-06 | 2017-06-08 | 서울대학교산학협력단 | G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물 |
TW201718557A (zh) * | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
TW201726128A (zh) * | 2015-10-08 | 2017-08-01 | 歌林達有限公司 | 經吡唑基取代之四氫哌喃基碸 |
EP3413921A4 (en) * | 2016-02-09 | 2019-08-14 | Alexander Krantz | SELECTIVE PROTEIN SITE FUNCTIONALIZATION USING TRACE-FREE AFFINITY MARKERS |
KR102573333B1 (ko) | 2016-06-28 | 2023-08-31 | 삼성디스플레이 주식회사 | 표시 장치 |
US10214492B2 (en) * | 2016-12-12 | 2019-02-26 | Vettore, LLC | Heterocyclic inhibitors of MCT4 |
WO2019090242A1 (en) | 2017-11-04 | 2019-05-09 | Advanced Proteome Therapeutics Inc. | Composition and method for modifying polypeptides |
JP6800492B2 (ja) * | 2018-06-29 | 2020-12-16 | MiZ株式会社 | 水素を含む癌性疼痛の抑制もしくは軽減のための組成物 |
WO2024036243A2 (en) * | 2022-08-10 | 2024-02-15 | Vettore, LLC | Salts of heterocyclic inhibitors of monocarboxylate transporter 4 for the treatment of disease |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US6117841A (en) * | 1997-05-30 | 2000-09-12 | Warner-Lambert Company | Substituted peptidylamine calcium channel blockers |
CA2415697A1 (en) * | 2000-07-13 | 2002-01-24 | James C. Forbes | Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
JP4537855B2 (ja) * | 2002-10-09 | 2010-09-08 | 久光製薬株式会社 | 抗真菌活性を有する新規ピラゾール化合物 |
CN1816332A (zh) * | 2003-05-30 | 2006-08-09 | 神经医药技术股份有限公司 | 3-氨基甲基-吡咯烷作为n-型钙通道阻断剂 |
AU2006331963A1 (en) * | 2005-12-22 | 2007-07-05 | Merck & Co., Inc. | Substituted piperidines as calcium channel blockers |
WO2009114451A1 (en) * | 2008-03-11 | 2009-09-17 | Danisco Us Inc., Genencor Division | Glucoamylase and buttiauxiella phytase during saccharification |
JP5421368B2 (ja) * | 2008-08-01 | 2014-02-19 | パーデュー、ファーマ、リミテッド、パートナーシップ | テトラヒドロピリジニルおよびジヒドロピロリル化合物およびそれらの使用 |
KR101052065B1 (ko) * | 2008-10-15 | 2011-07-27 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법 |
UA104010C2 (en) * | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
-
2013
- 2013-08-16 AU AU2013302471A patent/AU2013302471B2/en not_active Ceased
- 2013-08-16 KR KR20157006349A patent/KR20150042834A/ko not_active Application Discontinuation
- 2013-08-16 CN CN201380054106.3A patent/CN104903316B/zh not_active Expired - Fee Related
- 2013-08-16 CA CA2882123A patent/CA2882123C/en not_active Expired - Fee Related
- 2013-08-16 MX MX2015002038A patent/MX2015002038A/es not_active Application Discontinuation
- 2013-08-16 ES ES13753391.5T patent/ES2600743T3/es active Active
- 2013-08-16 JP JP2015527652A patent/JP2015524852A/ja not_active Withdrawn
- 2013-08-16 BR BR112015003395A patent/BR112015003395A2/pt not_active IP Right Cessation
- 2013-08-16 US US13/968,473 patent/US8901314B2/en active Active
- 2013-08-16 CN CN201711011681.1A patent/CN107857757A/zh active Pending
- 2013-08-16 WO PCT/US2013/055271 patent/WO2014028803A1/en active Application Filing
- 2013-08-16 SG SG11201501137VA patent/SG11201501137VA/en unknown
- 2013-08-16 EP EP13753391.5A patent/EP2885293B1/en active Active
- 2013-08-16 PE PE2015000208A patent/PE20151140A1/es not_active Application Discontinuation
- 2013-08-16 EA EA201590380A patent/EA201590380A1/ru unknown
-
2015
- 2015-02-10 CR CR20150069A patent/CR20150069A/es unknown
- 2015-02-11 IL IL237191A patent/IL237191A0/en unknown
- 2015-02-13 PH PH12015500315A patent/PH12015500315A1/en unknown
- 2015-02-16 CL CL2015000358A patent/CL2015000358A1/es unknown
-
2016
- 2016-03-11 HK HK16102720.5A patent/HK1214860A1/zh unknown
-
2017
- 2017-11-16 AU AU2017261551A patent/AU2017261551B2/en not_active Ceased
- 2017-12-26 JP JP2017249223A patent/JP6294559B1/ja not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9974775B2 (en) | 2013-08-16 | 2018-05-22 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
Also Published As
Publication number | Publication date |
---|---|
US20140163031A1 (en) | 2014-06-12 |
CR20150069A (es) | 2015-05-18 |
AU2013302471B2 (en) | 2017-08-17 |
EP2885293B1 (en) | 2016-07-27 |
CA2882123C (en) | 2021-07-20 |
PE20151140A1 (es) | 2015-08-07 |
JP6294559B1 (ja) | 2018-03-14 |
SG11201501137VA (en) | 2015-04-29 |
CN104903316A (zh) | 2015-09-09 |
CN107857757A (zh) | 2018-03-30 |
EA201590380A1 (ru) | 2015-07-30 |
JP2018065865A (ja) | 2018-04-26 |
WO2014028803A1 (en) | 2014-02-20 |
PH12015500315A1 (en) | 2015-03-30 |
JP2015524852A (ja) | 2015-08-27 |
US8901314B2 (en) | 2014-12-02 |
MX2015002038A (es) | 2016-01-22 |
CA2882123A1 (en) | 2014-02-20 |
BR112015003395A2 (pt) | 2017-07-04 |
KR20150042834A (ko) | 2015-04-21 |
AU2017261551B2 (en) | 2019-07-04 |
CL2015000358A1 (es) | 2015-06-12 |
IL237191A0 (en) | 2015-04-30 |
ES2600743T3 (es) | 2017-02-10 |
AU2017261551A1 (en) | 2017-12-07 |
AU2013302471A1 (en) | 2015-02-26 |
CN104903316B (zh) | 2017-11-28 |
EP2885293A1 (en) | 2015-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1214860A1 (zh) | 作為 型鈣通道阻滯劑的取代的吡唑 | |
IL237190A0 (en) | Pyrazoles are converted as n-type calcium channel blockers | |
HK1204513A1 (zh) | 質量驅動型流 | |
HK1248702A1 (zh) | 取代的吡咯烷-2-甲酰胺 | |
HK1200830A1 (zh) | 取代的吡咯烷- -甲酰胺 | |
HK1204341A1 (zh) | 基於適體的多元化試驗 | |
HK1201862A1 (zh) | 抗- -抗- 雙特異性抗體 | |
HK1206724A1 (zh) | 取代的苯並噻吩並嘧啶 | |
IL237192A0 (en) | Pyrrolopyrazoles as n-type calcium channel blockers | |
EP2934541A4 (en) | NORIBOGAINE SUBSTITUTE | |
HK1206022A1 (zh) | 取代的咪唑並噠嗪 | |
HK1217690A1 (zh) | 作爲 型鈣通道阻滯劑的環戊基吡唑 | |
GB2518990B (en) | Controls | |
HK1223939A1 (zh) | 取代咪唑用作 型鈣通道阻滯劑 | |
GB201210472D0 (en) | Obtaining control words | |
PL2617907T3 (pl) | Rynna szczelinowa | |
PL2634900T3 (pl) | Regulator elektryczny dwuprzewodowy | |
AU348221S (en) | Calibrator | |
GB201206745D0 (en) | N block | |
GB201203947D0 (en) | Novel methodology | |
GB201206473D0 (en) | Sandal system | |
GB201212393D0 (en) | Novel combination | |
GB201206268D0 (en) | Starting Line | |
GB201203956D0 (en) | Controls | |
GB201203954D0 (en) | Controls |